Becoming an Advocate for Phelan-McDermid Syndrome (PMS): Lacy and Avenly’s Story
Photo courtesy of Lacy Biram

Becoming an Advocate for Phelan-McDermid Syndrome (PMS): Lacy and Avenly’s Story

Prior to her daughter Avenly’s diagnosis, Lacy Biram had never before heard of Phelan-McDermid syndrome (PMS). Currently, there are an estimated 2,200-3,000 people worldwide who have this rare condition. For…

Continue Reading Becoming an Advocate for Phelan-McDermid Syndrome (PMS): Lacy and Avenly’s Story
Raising Phelan-McDermid Syndrome Awareness (And How YOU Can Get Involved at the EL-PFDD Meeting!): An Interview with Geraldine Bliss (Pt. 1)
Photo courtesy of Geraldine Bliss

Raising Phelan-McDermid Syndrome Awareness (And How YOU Can Get Involved at the EL-PFDD Meeting!): An Interview with Geraldine Bliss (Pt. 1)

On November 8th, 2022, CureSHANK is sponsoring an Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting for Phelan-McDermid Syndrome (PMS). Co-planned by the Phelan-McDermid Syndrome Foundation, this virtual EL-PFDD meeting will: [give]…

Continue Reading Raising Phelan-McDermid Syndrome Awareness (And How YOU Can Get Involved at the EL-PFDD Meeting!): An Interview with Geraldine Bliss (Pt. 1)
Compassion Corner: Study Examines Ways to Approach Patients When Doctors Deliver ‘Bad News’
source: pixabay.com

Compassion Corner: Study Examines Ways to Approach Patients When Doctors Deliver ‘Bad News’

Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…

Continue Reading Compassion Corner: Study Examines Ways to Approach Patients When Doctors Deliver ‘Bad News’
Early ERT Improves Pompe Disease Outcomes
source: shutterstock.com

Early ERT Improves Pompe Disease Outcomes

Enzyme replacement therapy (ERT) is an approved treatment strategy for those with Pompe disease. It involves providing patients with alpha-glucosidase, which helps to break down glycogen. In addition to reducing…

Continue Reading Early ERT Improves Pompe Disease Outcomes

World Alliance of Pituitary Organizations’ Webinar: Fighting Against the Global Issue of Substandard and Falsified (SF) Medical Products

  • Post author:
  • Post category:

Online Webinar: Fighting Against the Global Issue of Substandard (SF) and Falsified Medical Products With Dr. Bahijja Raimi-Abraham October 20, 2022 Dr Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics…

Continue Reading World Alliance of Pituitary Organizations’ Webinar: Fighting Against the Global Issue of Substandard and Falsified (SF) Medical Products
Could AI Predict Vasculitis and Spondyloarthritis?
Rosser1954 / CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)

Could AI Predict Vasculitis and Spondyloarthritis?

It’s no secret that receiving a rare disease diagnosis can take excess amounts of time. Various articles share that, on average, it takes anywhere from four to nine years for…

Continue Reading Could AI Predict Vasculitis and Spondyloarthritis?
RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids
source: shutterstock.com

RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids

On September 28, 2022, the Rare Disease Legislative Advocates (RDLA) hosted their monthly webinar. These webinar help provide updates to the rare disease community on legislation and other policy initiatives…

Continue Reading RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids
How “My Rare ID” Supports the Rare Disease Community: An Interview with Jeff Lord (Pt. 2)
My Rare ID logo

How “My Rare ID” Supports the Rare Disease Community: An Interview with Jeff Lord (Pt. 2)

Before you continue, make sure you've read Part 1 of our interview, where we discussed the Lord family's story and experience with rare disease, and the development of MobiMedQR. This tool, which…

Continue Reading How “My Rare ID” Supports the Rare Disease Community: An Interview with Jeff Lord (Pt. 2)